adenine has been researched along with selinexor in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beckwith, KA; Byrd, JC; Guinn, D; Hing, ZA; Johnson, AJ; Lapalombella, R; Lehman, AM; Mantel, R; Smith, LL; Williams, E; Williams, K; Woyach, JA | 1 |
| Kadri, S; Landesman, Y; Lee, J; Lu, P; Maltsev, N; Ming, M; Shacham, S; Sharma, S; Sukhanova, M; Wang, W; Wang, YL; Wu, W; Xie, B | 1 |
| Arribas, AJ; Bertoni, F; Cascione, L; Curti, E; Gaudio, E; Priebe, V; Rossi, D; Spriano, F; Stathis, A; Tarantelli, C; Zhang, L; Zucca, E | 1 |
| Abrisqueta, P; Bobillo, S; Boix, J; Bosch, F; Carabia, J; Castellví, J; Céspedes Torrez, DH; Crespo, M; Escoda, L; Jiménez, I; Martínez-Ricarte, F; Nieto, JC; Pagès, C; Palacio, C; Perla, C; Puigdefàbregas, L; Purroy, N; Seoane, J | 1 |
| Baker, S; Bhat, S; Byrd, JC; Canfield, D; Cempre, CB; Fu, Q; Hu, B; Huang, Y; Jaglowski, SM; Lapalombella, R; Lockman, H; Rogers, KA; Ruppert, AS; Shah, H; Stephens, DM; Vadeboncoeur, R; Walker, JS; Woyach, JA | 1 |
1 trial(s) available for adenine and selinexor
| Article | Year |
|---|---|
Selinexor Combined with Ibrutinib Demonstrates Tolerability and Safety in Advanced B-Cell Malignancies: A Phase I Study.
Topics: Adenine; Adult; Humans; Hydrazines; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Piperidines; Pyrazoles; Pyrimidines; Triazoles | 2022 |
4 other study(ies) available for adenine and selinexor
| Article | Year |
|---|---|
Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia.
Topics: Adenine; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Synergism; Humans; Hydrazines; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Piperidines; Pyrazoles; Pyrimidines; Triazoles; Xenograft Model Antitumor Assays | 2015 |
XPO1 Inhibitor Selinexor Overcomes Intrinsic Ibrutinib Resistance in Mantle Cell Lymphoma via Nuclear Retention of IκB.
Topics: Adenine; Apoptosis; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Exportin 1 Protein; Humans; Hydrazines; I-kappa B Proteins; Karyopherins; Lymphoma, Mantle-Cell; NF-kappa B; Piperidines; Protein Subunits; Pyrazoles; Pyrimidines; Receptors, Cytoplasmic and Nuclear; Triazoles | 2018 |
The Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) demonstrated synergies with other anti-lymphoma targeted agents.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cell Proliferation; Drug Synergism; Humans; Hydrazines; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Niacinamide; Piperidines; Pyrazoles; Pyrimidines; Sulfonamides; Triazoles; Tumor Cells, Cultured | 2019 |
Repolarization of tumor infiltrating macrophages and increased survival in mouse primary CNS lymphomas after XPO1 and BTK inhibition.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Central Nervous System Neoplasms; Drug Resistance, Neoplasm; Drug Synergism; Exportin 1 Protein; Female; Humans; Hydrazines; Karyopherins; Lymphoma, Non-Hodgkin; Macrophages; Mice; Mice, Nude; Piperidines; Receptors, Cytoplasmic and Nuclear; Survival Rate; Triazoles; Tumor Cells, Cultured; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2020 |